Research programme: cancer therapeutics - Stainwei Biotech

Drug Profile

Research programme: cancer therapeutics - Stainwei Biotech

Alternative Names: hAB 21; M23; P16

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator Stainwei Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors; Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 May 2017 hAB 21 is still in preclinical development for Cancer in China
  • 03 May 2017 Stainwei Biotech announces intention to submit IND for hAB 21 to the China FDA for Solid tumours (Late-stage disease) in the second half of 2017
  • 03 May 2017 Stainwei Biotech announces intention to submit IND for hAB 21 to the US FDA for Solid tumours (Late-stage disease) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top